GlassScriptPhysician profile
Rachel Harvey
NPI 1649950577
$4,495.79
in general payments reported to CMS, 2019-2025
22 companies · $1,545 in 2025
The $1,545 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $463 · 2024: $2,488 · 2025: $1,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,478 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,478.41 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $743.13 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $683.21 | 2023-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $502.51 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $426.75 | 2023-2025 | Sunosi |
| Insmed, INC. | $335.27 | 2024-2025 | Arikayce, Brinsupri |
| Pulmonx Corporation | $329.22 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Genzyme Corporation | $278.38 | 2024-2025 | |
| Verona Pharma, INC. | $215.49 | 2025 | Ohtuvayre |
| Amgen INC. | $199.82 | 2023-2025 | Tezspire, Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.40 | 2024-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $104.46 | 2024 | |
| Merck Sharp & Dohme LLC | $89.15 | 2024-2025 | Capvaxive, Zerbaxa, Recarbrio |
| Novartis Pharmaceuticals Corporation | $72.33 | 2023-2024 | |
| Harmony Biosciences LLC | $71.00 | 2024-2025 | |
| Mylan Specialty L.P. | $68.63 | 2023-2024 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $37.74 | 2024 | Hillrom - Vest System Model 105 Home Care |
| La Jolla Pharmaceutical Company | $37.44 | 2024 | Giapreza |
| Actelion Pharmaceuticals US, INC. | $34.03 | 2024 | Uptravi |
| Vifor Pharma, INC. | $24.61 | 2025 | Zemaira |
| Viatris Specialty LLC | $20.25 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $18.61 | 2024 | Terlivaz |
| Inogen, INC. | $13.36 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Harvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.